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Abstract
A nanocomposite hydrogel with photocrosslinkable micro-porous networks and a nanoclay 
component was successfully prepared to control the release of growth factor-rich stem cell 
secretome. The proven pro-angiogenic and cardioprotective potential of this new bioactive system 
provides a valuable therapeutic platform for cardiac tissue repair and regeneration.
Nanocomposite hydrogels have emerged as a valuable tool in tissue engineering and 
regenerative medicine as they provide tunable platforms to facilitate the formation of 
functional tissues.1–3 In addition, they can be used as a carrier of drugs or growth factors by 
selecting a suitable nanomaterial, which can efficiently interact with the loaded 
biomolecule.4 Specifically, the surface area, charge density and presence of reactive 
functionalities of the nanomaterial are the major parameters that dictate the loading 
efficiency and release kinetics. A variety of nanoscale materials are available for these 
applications, such as synthetic polymers, carbon-based nanotubes (CNTs), graphene oxide 
(GO) and nanodiamonds.5–8
These nanomaterials have been successfully embedded in polymeric networks as a delivery 
platform for therapeutics. However, their clinical potential in regenerative medicine, 
particularly for carbon based materials, is currently limited by inefficient loading of multiple 
therapeutic molecules, non-ideal release kinetics, biodegradability and associated 
cytotoxicity.9,10
A possible alternative to address these problems is the use of biodegradable, biocompatible, 
two dimensional synthetic nanoclay materials.11 LAPONITE® (Na0.7+ [(Si8Mg5.5Li0.3) 
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O20(OH)4]0.7−) is an example of synthetic clay from the smectite family that consists of 
disk-shaped particles with a diameter of approximately 25 nm and a 1 nm thickness.12,13 
These nanoparticles provide superior physical, chemical, and biological utility when 
compared to other 2D nanoparticles, such as graphene oxide, due to their uniform shape, 
discotic charged surface, and high surface-to-volume ratio.12 These properties allow for 
anisotropic interactions with anionic, cationic, and neutral polymers to form physically 
crosslinked networks. In addition, these same interactions can be useful in modulating the 
release kinetics of drugs and biomolecules.14 A previous study has reported successful 
retention and controlled release of vascular endothelial growth factors (VEGF) by adsorbing 
to the bioactive LAPONITE® surface through electrostatic interactions. 15 The VEGF/
LAPONITE® complex was then encapsulated in a collagen scaffold showing enhanced 
angiogenesis in vivo when compared to a collagen scaffold just containing VEGF. This 
result was attributed to the sustained release in the presence of the synthetic clay.
Nonetheless, scientists have proven that the delivery of multiple growth factors 
simultaneously can provide an increased therapeutic benefit when compared to 
monotherapy.16–18 This is particularly true for cardiovascular diseases in which a mixture of 
paracrine growth factors has been shown to promote local angiogenesis and regenerate 
myocardial tissue. A natural way of producing growth factor-rich conditioned media, also 
known as secretome, is culturing mesenchymal stem cells (MSCs) under specific stressful 
conditions such as hypoxia and serum deprivation.
The secretome, isolated from MSCs, has been shown to have cardioprotective abilities, as 
well as, promote angiogenesis when injected into the peri-infarct area.19–21 However, the 
efficacy of this treatment has been hindered by the lack of retention of the secretome 
components at the site of injury. A nanocomposite hydrogel platform may offer a possible 
solution to achieve its full therapeutic benefits. This method will also offer an alternate 
strategy to the widely used stem cell transplantation approach for delivering the paracrine 
factors.
Here we investigated the possibility of using LAPONITE® nanosilicates and gelatin 
methacrylate (GelMA) to form a nanocomposite hydrogel for controlled release of stem cell 
secretome. The overall efficacy of this therapeutic device will be determined following the 
assessment of two main objectives. First, the effect of nanoclay in controlling the release 
kinetics of the growth factors present in the secretome needs to be assessed. Second, the pro-
angiogenic and cardioprotective ability of the bioactive nanocomposite hydrogel had to be 
determined. These two aspects are necessary for the successful application of this 
nanocomposite hydrogel for cardiac regeneration as shown in the schematic (Fig. 1).
To efficiently harness a high concentration of secretome, human bone marrow-derived 
mesenchymal stem cell (hMSC) spheroids were prepared. This method was chosen because 
spheroid culture provides a high ratio of cells to media volume that allows for the production 
of a highly concentrated secretome. Microfabrication technology was used to develop 
microscale arrayed wells in order to generate the hMSC spheroids.22 Concave microwells 
(300 µm wide) were fabricated starting from microfluidic channels combined with 
pentagonal chambers using polydimethylsiloxane (PDMS). Subsequently, a PDMS solution 
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was introduced into the microfluidic channel filling these chambers. Finally, using suction 
and a pressing and rolling technique the excess PDMS solution was removed from the 
chambers. This leads to the production of the concave microwells after curing of the 
remaining PDMS solution. The formation of this final product is directly attributed to the 
surface tension of PDMS (Fig. 2A). An hMSC suspension was introduced into the culture 
device through the inlet port which resulted in a uniform number of cells trapped in each 
concave well (Fig. 2B). Spheroids were cultured for 48 hours in order to promote the 
secretion of paracrine factors. The amount of growth factors in the media was quantified 
using ELISA and compared to hMSCs cultured in 2D under the same conditions. 
Specifically, the amount of vascular endothelial growth factor (VEGF), fibroblast growth 
factor 2 (FGF2), angiogenin, and bone morphogenetic protein 2 (BMP2) were found to be 
significantly higher in the spheroid culture (Fig. 2C). Among all the bioactive molecules, 
these were chosen due to their integral role in cardiac regeneration by promoting 
angiogenesis, attenuating apoptotic pathways, and remodelling the damaged myocardium.23
A possible strategy to improve their therapeutic efficacy is to design a delivery platform that 
can control their release over time in the site of cardiac injury. For this reason, different 
nanocomposite photochemical hydrogels based on GelMA and LAPONITE® were 
fabricated for the delivery of secretome. GelMA is a chemically modified version of gelatin 
that can easily form a photo-crosslinkable hydrogel due to the presence of methacrylic 
groups. The systems tested in this study were prepared using GelMA (5.0% w/v) with a 
medium degree of methacrylation (~50% amine substitution).24 The presence of a 
microporous network was confirmed by scanning electron microscopy (SEM) (Fig. 2D). The 
concentration of LAPONITE® was shown to have no effect on the porosity of the hydrogel 
network (Fig. S1†). The influence of LAPONITE® over the mechanical properties of the 
photo-crosslinkable hydrogel was investigated through unconfined uniaxial cyclic 
compression studies (Fig. 2E). As the concentration of LAPONITE® in the GelMA 
hydrogel was increased from 0.4% to 1% w/v a corresponding enhancement in the 
mechanical properties was observed. As expected, GelMA hydrogels with the highest 
concentration of nanoclay showed the greatest Young’s Modulus value (Fig. 2F). This 
observed increase in stiffness is comparable to previously reported results using the same 
nanocomposite system.12 These results can potentially be attributed to the electrostatic 
interactions between the surface of the clay and the polymer chains.25 The very same 
electrostatic interactions can play a fundamental role in modulating the release of the 
previously mentioned growth factors. For this reason, the in vitro release studies in PBS 
were carried out for VEGF and FGF2 to assess how the concentration of LAPONITE® 
could affect their release kinetics (Fig. 2G and H). A better control over the release of VEGF 
and FGF2 was observed in the formulations containing the higher amount of clay although 
no significant difference in the swelling behaviour was detected between the groups (Fig. 
S2†). Specifically, LAPONITE® was able to slow down the amount of growth factors 
released over time (15 days). This observed effect was directly dependent on clay 
concentration. We hypothesize that the mechanism responsible for the controlled release of 
VEGF and FGF2 is mainly due to electrostatic interactions between the growth factors and 
LAPONITE®, however, hydrogen bonding and ion–dipole interactions could also be 
involved. In addition, the nanocomposite hydrogels (0.8% and 1.0% w/v), minimized the 
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initial amount of growth factor detected (t = 0). This indicates that the increase in 
LAPONITE® concentration leads to a more compact matrix capable of better retaining the 
growth factors for a prolonged period of time. For this reason nanocomposite hydrogels with 
a concentration less than 0.8% w/v were not further considered in the study.
Next, the angiogenic potential of the hydrogels was tested in order to evaluate the bioactivity 
of the nanocomposite hydrogel using HUVECs as a model cell line. In particular, 
nanocomposite hydrogels loaded with secretome were further tested to prove their ability to 
influence HUVEC proliferation overtime. Growth factors were loaded by mixing the 
secretome solution with GelMA prior to UV gelation, therefore, it was necessary to verify 
whether the therapeutic ability of secretome is maintained after the photo-crosslinking 
process. HUVEC (3 × 106 cells per ml) were encapsulated in three different groups: GelMA 
hydrogel (Ctrl Gel), GelMA/LAPONITE® hydrogel (NS Gel), and GelMA/LAPONITE® 
secretome loaded hydrogel (NS Gel+). All of the studies reported used a nanocomposite 
hydrogel with a LAPONITE® concentration of 0.8% w/v. Results using 1.0% w/v of 
LAPONITE® were included in the ESI† as the stiffness of the matrix hindered the HUVEC 
spreading in the 3D polymeric network (Fig. S3†).
At day 3 a statistically significant increase in HUVEC proliferation was observed for the NS 
Gel+ (Fig. 3A) with respect to the other groups. In addition, the formation of tubular-like 
structures was more evident in the NS Gel+ system (Fig. 3B) indicating the formation of a 
more mature cell network. HUVECs were able to spread throughout the total thickness of 
the NS Gel+ at day 3 (Fig. 3C) as shown by the 3D reconstruction of the gel using confocal 
imaging. Subsequently, a microchannel migration assay was used to further assess the 
angiogenesis potential of the NS Gel+ system. The microchannel was fabricated throughout 
the thickness of the hydrogels by inserting a 200 µm needle into the polymeric solution prior 
to gelation (Fig. 3D). NS Gel+ showed the greatest potential for lumen formation due to a 
significant increase in percentage of microchannel area covered (53.5 ± 11.7%) when 
compared to the Ctrl Gel (25.4 ± 3.3%) and NS Gel (22.6 ± 6%). Overall these findings 
suggest that the bioactivity of the loaded secretome was not lost after gel formation as 
demonstrated by the positive influence on HUVEC proliferation and their reorganization 
into monolayers. These two factors represent fundamental aspects of angiogenesis, which is 
essential for the regeneration of cardiac tissue.
Apart from angiogenesis, another important mechanism influencing the recovery of cardiac 
function is the prevention of cell apoptosis and necrosis. Soluble paracrine factors present in 
secretome have been shown to have an antiapototic paracrine effect essential for the 
improvement of heart function post-infarction.26 For this reason, the antiapoptotic paracrine 
effect of the secretome loaded nanocomposite hydrogels was another focus of this study.
Cardiomyocytes (CMs) were seeded on the NS Gel+ in 24 wellplate (105 cells per well) and 
cultured for 3 days (Fig. 4A). Fluorescent phalloidin (F-actin) and DAPI (nuclei) staining 
showed morphology indicative of healthy CMs. (Fig. 4B). Then an induction of cell 
apoptosis was necessary in order to mimic the conditions present in the post-infarct 
myocardium. This was accomplished by culturing the cells in hypoxia (1% O2) and serum 
deprived conditions (0% FBS) for 24 hours after the confirmation of their beating 
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functionality. A TUNEL assay was used to detect the presence of apoptotic cells on the 
different hydrogels characterized by double-stranded DNA breaks (Fig. 4C). In the Ctrl Gel 
and NS Gel an increase in the presence of red staining was observed, which is indicative of 
apoptotic cells. On the contrary CMs seeded on the NS Gel+ showed a minimal amount of 
red staining. This result confirms the cardioprotective ability of secretome which is capable 
of increasing cardiomyocyte survival and preserving CMs morphology. Specifically, the 
percentage of apoptotic cells was significantly lower in the NS Gel+ (15.7 ± 3.4%) than the 
other groups (Ctrl Gel: 28.6 ± 1.8%; NS Gel: 27.1 ± 4.9%) (Fig. 4D). However, MTS assay 
showed no significant difference in the amount of necrotic cardiomyocyte cells. Another 
method to confirm the beneficial anti-apoptotic ability of the loaded secretome in the 
nanocomposite hydrogels is to quantify the production of reactive oxygen species (ROS). An 
increase in relative fluorescence intensity, indicative of ROS production, was observed only 
in the Ctrl Gel and NS Gel, whereas no significant change was detected for the NS Gel+ 
system after 24 hours of induced apoptosis (Fig. 4E). In addition, activity of Caspase 3/7 
was evaluated for 12 hours, as they represent important proteases involved in the execution-
phase of cell apoptosis. Throughout the experiment a higher enzymatic activity was detected 
for the Ctrl Gel and NS Gel compared to the NS Gel+ confirming the protective ability of 
the loaded secretome in reducing the apoptosis process (Fig. 4F).
Conclusions
In conclusion, we report two principal findings. First, nanoclay can modulate the controlled 
release of multiple key growth factors present in stem cell derived secretome. The possible 
mechanism dictating this release profile is electrostatic interactions between the highly 
charged surface of LAPONITE® nanoplatelets and the growth factors of the secretome. 
Second, a stem cell derived secretome loaded nanocomposite hydrogel provides a dual 
action therapeutic system through its proangiogenic and cardioprotective ability. After the 
hydrogel is implanted into the damaged myocardium, this approach has the potential to 
increase the therapeutic efficacy of stem cell derived secretome for cardiac regeneration by 
increasing its retention in the site of injury. Therefore, the encapsulation of stem cell derived 
secretome in a nanocomposite hydrogel provides a promising alternative to stem cell therapy 
for the regeneration of cardiac tissue post myocardial infarction.
Methods
Materials
Synthetic silicate nanoplatelets (LAPONITE® XLG) SiO2 (59.5%), MgO (27.5%), Na2O 
(2.8%) and Li2O (0.8%) with low heavy metals content were supplied by Southern Clay 
Products, Inc. (Louisville). Gelatin type A from porcine skin, methacrylic anhydride, 
Irgacure 2959, were used without further modification from the manufacturer (Sigma-
Aldrich, St Louis, MO).
Preparation of the nanocomposite hydrogels
Nanocomposite hydrogels were prepared by mixing a GelMA solution (5% w/v) with 
different concentrations of LAPONITE® (0.4, 0.8, and 1.0% w/v). Irgacure 2959 (0.5% 
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w/v) was added prior to photoirradiation under UV light. In order to load the nanocomposite 
hydrogels with secretome 250 µL of polymeric mixture was combined with the 250 µL of 
media containing secretome prior to photoirradiation. Hydrogels with a thickness of 
approximately 3.5 mm and a diameter of 4 mm were photocrosslinked at 5 mW cm−2 for 10 
minutes for mechanical testing. Young’s Modulus was calculated using the slope of the 
stress strain curve in the region up to 10% of strain.27
Harnessing the MSC secretome using a microfluidic device
A microfluidic device was fabricated using a method previously reported.22 hMSCs were 
first cultured in 2D conditions using DMEM supplemented with 1% L-glutamine, 1% 
penicillin/streptomycin, and 10% FBS. hMSCs (passage 2–5) were then trypsinized and a 
250 µL solution with a cell density of 5 × 106 cells per ml was injected into the device 
ensuring an even distribution throughout all the wells. The hMSCs were incubated in a 
vertical position at 37 °C incubator for 48 h to allow formation of spheroids and secretion of 
paracrine factors in conditioned media (secretome). Quantification of the growth factors in 
the secretome was carried out using respective ELISA kits (R&D Systems).
Characterization of nanocomposite hydrogels
Compression studies of the nanocomposite hydrogels were investigated using an RSA-III 
dynamic mechanical analyser (TA Instrument; New Castle, NE). Samples were cyclically 
compressed (n = 2) up to 25% of their original height at a rate of 0.005 mm s−1 in order to 
obtain stress versus strain curves. Then, the compressive modulus was calculated as the 
slope of the stress versus strain curve from 0% to 10% strain. After the mechanical 
characterization, secretome release kinetic studies were carried out. The secretome loaded 
nanocomposite hydrogels were incubated at 37 °C in 100 µL of phosphate buffer solution 
(PBS) for 15 days. The PBS was changed every 3 days and ELISA was used to quantify the 
amount of VEGF and FGF2 in the PBS incubation solution at each time point.
Analysis of angiogenic potential of hydrogels
For cell study purposes, HUVECs were cultured in normal endothelial growth medium with 
growth supplements (EGM-2 BulletKit without additional VEGF and FGF, Lonza, 
Walkersville, MD) and 1% penicillin/streptomycin. Passage 6–9 HUVECs were used in all 
3D encapsulation experiments. Prior to encapsulation experiments, HUVECs were 
trypsinized, centrifuged to obtain a pellet, and mixed with GelMA/LAPONITE® polymeric 
solution under sterile conditions. The HUVEC cell density in the polymer solution was 3 × 
106 cells per mL. Each gel was fabricated in a 96 well plate by adding 50 µL of the cell 
suspended hydrogels from different groups (equal volume of secretome and prepolymer gel 
for NS+ group). After photocrosslinking for one minute, the gels containing cells were 
grown for 3 days. Calcein staining was performed to investigate the morphology of the cells 
and the stained gels were washed with DPBS and high-resolution z-stack images were 
obtained using a confocal microscope (Olympus FV1200). For the microchannel migration 
assay, HUVECs were suspended in culture media (without VEGF and FGF) and seeded 
inside the microchannels. After 36 hours, photomicrographs were taken and analysed in 
Image J for percentage of area covered by adhered and migrated HUVECs in the different 
experimental groups.28
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Analysis of the cardioprotective properties of hydrogels
All experimental procedures were performed in accordance with the standard human care 
guidelines of the Guide for the Care and Use of Laboratory Animals published by the US 
National Institutes of Health (NIH Publication No. 85-23, revised 1996) and protocol No. 
15-06-17-01 approved by the Institutional Animal Care and Use Committee, University of 
Cincinnati. The neonatal CMs used for this study were isolated from newborn (1–3 day) 
Fisher-344 rat pups using the Worthington Neonatal CMs Isolation System (Worthington 
Biochemical) following the manufacturer’s protocol and earlier published work.29 Minced 
harvested hearts were enzymatically digested by incubation overnight at 4° C in trypsin 50 
mg mL−1. The tissue was then oxygenated for 1 min and incubated with 5 mL collagenase at 
a concentration of 300 U mL−1 on the shaker (2–4 rounds per min) for 30–45 min at 37 °C. 
Following this, the tissue was oxygenated and triturated several times, and undigested tissue 
was filtered out. The cells were allowed to settle for 20 min at an ambient temperature and 
centrifuged at 100g for 5 min before preplating twice (45 min each) in DMEM media 
(Hyclone), supplemented with 10% FBS (Hyclone) and Penicillin/Streptomycin at 37 °C.
After culturing CMs for 48 hours on the hydrogels in 10% FBS and 5% O2, the culture 
conditions were changed to 0% FBS and 1% O2 for 24 hours to induce cell apoptosis. The 
resulting cell apoptosis was quantified by monitoring Caspase 3/7 activity using an Apo-
ONE® Caspase-3/7 Assay (Promga) for 12 hours and using a Dead EndTM Colorimetric 
TUNEL Assay (Promega).30,31 Cell necrosis was quantified using an MTS assay. ROS 
production under previously mentioned stressed condition on different hydrogel 
formulations was determined by Intracellular ROS assay at 0 hour and 24 hour using 
fluorescence imaging.
Statistical analysis
Quantitative variables are presented as mean ± Standard Deviation (SD) from independent 
experiments as described in the figure legends. Statistics were performed using two-way 
and/or one-way Analysis of variance (ANOVA) by Bonferroni’s multiple comparison post 
hoc test. All statistical analyses were performed with Prism 5 (GraphPad Software). P value 
<0.05 was considered significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Concept in schematic. (1) Photo-crosslinlkable nanocomposite hydrogels comprised of 
silicate nanoplatelets, GelMA and hMSC derived growth factors (secretome). (2) 
Microbioreactor with deep concave wells to harness hMSC secretome. (3) Photo-crosslinked 
nanocomposite hydrogel encapsulating secretome. (4) The hydrogel can promote endothelial 
proliferation, migration and significantly attenuate cardiac cell apoptosis under stressed 
(hypoxic and serum starved) conditions.
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In vitro characterization of the developed nanocomposite hydrogel carrying secretome of 
hMSC spheroids. (A) Microfluidic chip with concave microwell array. Optical microscopy 
image of the microfluidic chip (Scale bar: 1 mm). (B) hMSC spheroid formation in the deep 
concave microwell arrayed microfluidic chip (Scale bar: 500 µm). (C) After 48 h, the 
conditioned media (secretome) was harvested from the microfluidic chip leaving behind the 
spheroids. hMSC spheroids secreted higher concentration of growth factors (VEGF, FGF, 
Angiogenin and BMP2) compared to 2D culture in plates as quantified by ELISA. (D) 
Scanning electron microscopic images of 0% and 0.8% NS hydrogels demonstrate the 
porous microstructures of the hydrogel (Scale bar: 100 µm). (E and F) Cyclic stress versus 
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strain curves and corresponding compressive modulus of the hydrogel showing the effect of 
LAPONITE® concentration over the mechanical properties (G and H) Effect of NS 
concentration on release of VEGF and FGF2 growth factors from different NS hydrogel 
formulations over time. *** = P < 0.001, n = 3.
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Angiogenic potential of the developed bioactive nanocomposite hydrogel. (A) Proliferation 
of HUVECs in 3D hydrogels with (NS Gel+) and without secretome (NS Gel). As a control 
group, hydrogel without NS (Ctrl Gel) was used. Cell proliferation was detected by MTS 
colorimetric assay while data (n = 3) presented in the graph were normalized with data from 
the control gel group at Day 0. NS+ Gel group showed significantly higher proliferation 
compared to other groups. (B) Representative photomicrographs of calcien stained HUVECs 
encapsulated in each hydrogel group. Importantly, HUVEC in NS+ Gel group also 
demonstrated highly branched tube-like structures which were absent in other groups. (C) 
Confocal fluorescence microscope image of HUVECs grown in 3D NS+ hydrogel, with blue 
nuclei stained with DAPI. The image confirms proliferation of the HUVEC all throughout 
the thickness of the hydrogel with highly branched tube-like microstructures. (D) i–ii. 
HUVEC adhesion and migration assay inside microchannels fabricated from the different 
hydrogel groups. The microchannel was made by needle (200 µm) insertions and 
photocrosslinking. Data are expressed as mean value ± Standard Deviation (SD). *** = P < 
0.001 compared to Control Gel, n = 3. (Scale bar: 100 µm).
Waters et al. Page 12














Cardioprotective nature of the developed bioactive nanocomposite hydrogel. (A) Schematic 
of culturing neonatal CMs on nanocomposite hydrogels. (B) Fluorescence microscope 
images of CMs grown in standard condition on NS+ hydrogel. The cells were 
immunostained with cardiac specific marker, sarcomeric α-actinin, and nuclei with DAPI 
(Scale bar: 10 µm). (C and D) Apoptosis assay on CMs under stressed condition by Deadend 
Colorimetric TUNEL assay. (Scale: bar: 50 µm). Number of apoptotic cells per well was 
quantified and represented in graph as percentage apoptotic cells per group. MTS assay was 
also performed to quantify the percentage of necrotic cells. The picture on lower right panel 
shows CM cells grown on the NS+ hydrogel under the above mentioned stressed condition 
still retained expression of intact cardiac marker, sarcomeric α-actinin. (E) Detection of 
ROS-induced apoptosis. Intracellular ROS quantified in terms of relative fluorescence 
intensities normalized to Ctrl gel value at 0 h. (F and G) To investigate the anti-apoptotic 
effects of the NS+ hydrogel, Caspase-3/7 activity was measured as an early indicator of 
apoptosis using Apo-ONE® homogeneous caspase-3/7 assay Kit (Promega, Madison, WI, 
Waters et al. Page 13













USA). Data are expressed as mean value ± Standard Deviation (SD). *** = P < 0.001 and ** 
= P < 0.01 compared to Control Gel, n = 3.
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